NRC Stock Chart & Stats
€1.54
€0.03(1.62%)
At close: 4:00 PM EDT
€1.54
€0.03(1.62%)
Day’s Range― - ―
52-Week Range€0.98 - €2.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€144.85M
Enterprise Value€160.20M
Total Cash (Recent Filing)€19.43M
Total Debt (Recent Filing)€86.52M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 10, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,197,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.91Price Target Upside218.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)€142.44M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue growth of 228% shows substantial expansion in the commercial base, while a roughly 48% gross margin indicates the platform can retain meaningful economics as sales scale. If sustained, this combination can support reinvestment and eventual operating leverage.
Improving ProfitabilityHigher gross margin, lower operating expenses, and positive adjusted EBITDA demonstrate tangible progress toward a more efficient operating model. These improvements can provide a foundation for narrowing losses and developing sustainable profitability if revenue growth and cost discipline continue.
Recurring Platform Revenue ModelNeuroStar combines system sales with recurring consumables and service revenue linked to installed equipment and patient treatments. This model can deepen customer relationships, improve revenue visibility, and increase the economic value of each provider placement over time.
Bears Say
Persistent Operating LossesDespite strong revenue growth and improved losses, the company remains materially unprofitable at both the EBIT and net-income levels. Continued negative margins indicate that scale has not yet produced consistent operating leverage, leaving execution dependent on further efficiency gains.
Ongoing Cash BurnNegative operating and free cash flow means the business is not yet funding its operations internally. Although the burn rate has improved from earlier periods, continued cash consumption can require additional financing and leaves less flexibility to invest in growth or absorb execution setbacks.
High Financial LeverageVery high leverage and a relatively small equity base constrain financial flexibility while the company is still loss-making. This structure increases dependence on improved operating performance and can heighten refinancing or dilution pressure if cash generation does not become sustainable.
Neuronetics News
NRC FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was €0.98 and its highest was €2.74 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is €144.85M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 29 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Aug 11, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €0.065.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.08.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 76,197,220 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 34.545%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in DE:NRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.91 (218.75% Upside)
€4.91 (218.75% Upside)
Blogger Sentiment
Bullish
DE:NRC Sentiment 67%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €39.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.55%
12-Months-Change
Fundamentals
Return on Equity
-150.56%
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neuronetics Inc
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
NRC Company Deck
NRC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed measurable operational and financial progress: revenue growth (9.1%), strong Greenbrook performance (+16.8%), margin expansion (to 51.1%), reduced OPEX (-12%), an improved net loss and a positive adjusted EBITDA, plus strengthened cash and an ATM raise. These positives were balanced against execution and timing risks centered on NeuroStar's transition (NeuroStar revenue down 2.7% and sessions down double digits due to inventory normalization and mix shifts), underused clinic capacity (~40%), potential short-term revenue choppiness as customers migrate to new purchase/lease models, and dependence on external regulatory timelines for psychedelics. On balance, the company demonstrated tangible progress toward profitability and cash generation while acknowledging near-term mix and execution challenges.View all DE:NRC earnings summariesNRC Stock 12 Month Forecast
Average Price Target
€4.91
▲(218.75% Upside)